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The P2X1 receptor belongs to a family of oligomeric
ATP-gated ion channels with intracellular N and C ter-
mini and two transmembrane segments separating a
large extracellular domain. Here, we describe a natu-
rally occurring dominant negative P2X1 mutant. This
mutant lacks one leucine within a stretch of four leucine
residues in its second transmembrane domain (TM2)
(amino acids 351–354). Confocal microscopy revealed
proper plasma membrane localization of the mutant in
stably transfected HEK293 cells. Nevertheless, voltage-
clamped HEK293 cells expressing mutated P2X1 chan-
nels failed to develop an ATP or ADP-induced current.
Furthermore, when co-expressed with the wild type re-
ceptor in Xenopus oocytes, the mutated protein exhib-
ited a dose-dependent dominant negative effect on the
normal ATP or ADP-induced P2X1 channel activity.
These data indicate that deletion of a single apolar
amino acid residue at the inner border of the P2X1 TM2
generates a nonfunctional channel. The inactive and
dominant negative form of the P2X1 receptor may con-
stitute a new tool for the study of the physiological role
of this channel in native cells.
The P2X receptors are oligomeric nonselective ATP-gated
cation channels that are expressed in many excitable and non-
excitable cells where they mediate a variety of physiological
actions, including central and peripheral neurotransmission,
smooth muscle contraction, and hormone secretion (1, 2). Seven
P2X receptors have been identified at the molecular level (3).
The P2X1 receptor subtype is found primarily on visceral and
vascular smooth muscle cells (4), but is also present in large
quantities on platelets (5). In these tissues, the P2X1 receptors
account for the rapidly inactivating a,b2methylene ATP-sen-
sitive native P2X receptor phenotype (4, 6). However, because
of the lack of potent and selective P2X receptor antagonists, the
physiological role of P2X1 receptors has been difficult to un-
ravel. Recently, the generation of P2X1 receptor-deficient mice
demonstrated that P2X1 receptors are essential for normal
male reproductive function via their role in vas deferens con-
traction in response to sympathetic nerve stimulation (7). How-
ever, its role in platelet function remains unclear (8).
Several mutagenesis analyses have been performed to iden-
tify P2X receptor subdomains involved in hetero- and homo-
oligomeric subunit assembly (9), and in the control of receptor
desensitization (10–12), or to identify amino acid residues con-
tributing to the pore of P2X channels (13, 14). Still little is
known about P2X receptor primary or secondary structures
participating in membrane sidedness, subunit stoichiometry,
ligand binding site, and gating properties of the channels.
We have identified a mutation in the platelet P2X1 receptor
of a patient showing a severe bleeding disorder. This mutation
corresponds to the loss of one leucine residue located between
leucine residues 351–353 at the inner border of the second
transmembrane domain of the channel. The single amino acid
residue deletion resulted in the expression of nonfunctional
channels in HEK293 cells. Furthermore, the mutated receptor
acted as a dominant negative molecule when co-expressed with
the wild type receptor in Xenopus oocytes.
EXPERIMENTAL PROCEDURES
Patient Description—The propositus is a 6-year-old girl, second child
of two healthy unrelated parents; her sister is healthy. She was referred
to our hospital at the age of 19 months because of pronounced bleeding:
after a fulminant nose bleed, she was hospitalized in the intensive care
unit for severe exsanguination (hemoglobin drop from 121 to 60 g/liter).
Local examination of the nasal mucosa revealed diffuse oozing, without
local vascular dilatation. Recurrent bleeding was evidenced by low
plasma iron levels and increased reticulocyte numbers. Further spon-
taneous mucosal nose bleeding could be stopped only by administration
of tranexamic acid and platelet transfusions. Moreover, she continu-
ously has spontaneous generalized petechiae and ecchymoses. Coagu-
lation parameters, von Willebrand factor antigen, and function were
completely normal. Platelet count and size were normal as well as
platelet morphology, studied by electron microscopy. Platelet aggrega-
tion in response to the 14-mer TRAP peptide, arachidonic acid, and
ristocetin was unaltered. The patient showed, however, a selective
impairment of the ADP-induced platelet aggregations.
Natural Mutation in the P2X1 Receptor cDNA and Expression Vec-
tors—Full-length patient platelet P2X1 cDNAs were obtained by re-
verse transcriptase-polymerase chain reaction using primers encompa-
ssing the coding region of the cDNA: P2X1, 59-CCCACCATGGCACGG-
CGGTTCCAGGAGG-39 (sense), 59-TCAGGATGTCCTCATGTTCTCCT-
GCAGG-39 (antisense). The polymerase chain reaction fragments were
cloned into the PCR2.1-TOPO vector (TOPO TA cloning kit, InVitro-
gen). Individual clones were sequenced using the AutoRead Sequencing
kit (Amersham Pharmacia Biotech) on the automated A.L.F. sequencer
(Amersham Pharmacia Biotech). PCR2.1-TOPO vector clones contain-
ing either wild type (P2X1WT) or mutated (P2X1delL) cDNAs were
digested with EcoRI restriction enzyme, and the purified fragments
were subcloned into the EcoRI-digested pcDNA3.1 (InVitrogen) or bi-
cistronic pCINeoIRES-GFP1 (15) expression vectors. The resulting ex-
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pression vectors were used for T7 promoter driven in vitro transcription
(RiboMax Large Scale RNA Production System, Promega) for injection
into Xenopus oocytes or transfection of HEK293 cells (FuGene 6 rea-
gent, Roche Molecular Biochemicals).
Cell Culture and Xenopus Oocyte Isolation and Microinjection—
HEK293 cells were maintained in Dulbecco’s modified Eagle’s medium
cell culture medium supplemented with 2% penicillin-streptomycin, 2%
L-glutamine, 1% nonessential amino acids and 10% fetal bovine serum
(Life Technologies, Inc.). Stable transfectants were obtained via selec-
tion with G418 (800 mg/ml). Ovarian lobes were removed from mature
female Xenopus laevis, treated with 2 mg/ml collagenase A (Roche
Molecular Biochemicals) for 1.5–2 h, and stage V and VI oocytes were
selected. After cytoplasmic microinjections, the oocytes were incubated
for 48–72 h at 18 °C in ND 96 solution (96 mM NaCl, 2 mM KCl, 1 mM
MgCl2, 1.8 mM CaCl2, 5 mM Hepes, pH 7.5, 100 units/ml penicillin-
streptomycin, 2.5 mM sodium pyruvate).
Preparation of P2X1-specific Antiserum and Western Blotting—A
rabbit antiserum specific to the extracellular domain of human P2X1
was obtained by injection of a homemade glutathione S-transferase
protein fused to amino acid residues 61–318 of the P2X1 receptor using
standard methods. Cytosolic and membrane fractions of HEK293 cell
extracts were analyzed in Western blotting using this antiserum. Pro-
tein concentrations in the extracts were determined using the Bradford
assay.
Immunostaining and Confocal Microscopy—Stably transfected
HEK293 cells were plated on polylysine-coated (0.1 mg/ml, Sigma)
culture slides at 5 3 105 cells/ml density. Fixed (methanol) and perme-
abilized (1% Triton X-100) cells were incubated with the polyclonal
rabbit P2X1 antiserum, before detection with goat anti-rabbit-fluores-
cein isothiocyanate (Dako A/S, Glostrup, Denmark). Immunofluores-
cence was visualized in a Zeiss LSM510 confocal microscope (3 40
magnification).
Electrophysiological Recordings—Transfected HEK293 cells were
analyzed 36–72 h after transfection using the whole cell patch clamp
method. The standard external bath solution contained 150 mM NaCl, 6
mM CsCl, 1 mM MgCl2, 1.5 mM CaCl2, 10 mM Hepes, 10 mM glucose, 50
mM mannitol, pH 7.4. The pipette solution contained: 40 mM CsCl, 100
mM aspartic acid, 1 mM MgCl2, 10 mM Hepes, 5 mM EGTA, 1.928 mM
CaCl2, pH 7.2. Pipette resistance was between 7.5 and 2.5 megohms.
Whole cell currents in the ruptured membrane mode were continuously
recorded for 10 s at 280 mV holding potential. To determine IV rela-
tionship, we applied short (500 ms) RAMP (from 2100 to 1100 mV)
before and during agonist application. The agonists were applied using
a fast application system. Current measurements on Xenopus oocytes
were performed by a two-electrode voltage clamp technique. Oocytes
were maintained in a continuously perfused (3 ml/min) small volume
(250 ml) chamber. 100 mM niflumic acid was added in the external ND 96
solution to prevent activation of endogenous Ca21-dependent chloride
channels. The currents were recorded at 260 mV holding potential. The
P2X1 channel-generated inward current was activated by applying 250
ml of 100 mM ATP solution from a pipette above the oocyte. Data were
analyzed with WinASCD 5.0 software (G. Droogmans, Leuven, Bel-
gium). Statistical comparison was made using the nonpaired Student’s
t test.
RESULTS
Normal Membrane Localization of P2X1delL Channels—The
mutation described is an in-frame deletion of three nucleotides
in the sequence CTGCTGCTG located between positions 1051
and 1059 of the patient platelet P2X1 cDNAs (Fig. 1, A and B).
Both normal and mutated P2X1 cDNAs were identified in the
patient’s platelets. Neither P2X1 cDNAs from the patient re-
ticulocytes nor the P2X1 gene from the patient neutrophil and
mononuclear cells contained the mutation, which is thus likely
of clonal origin. The P2X ionotropic receptors have two putative
transmembrane domains (TM1 and TM2) separated by a large
extracellular region, with both the N and C termini located
inside the cell (3). The mutation results in deletion of one of the
Leu-351, Leu-352, or Leu-353 residues within a stretch of four
leucine residues contained in the TM2 domain of the P2X1
receptor (amino acids 351–354) (Fig. 1C). To compare the sub-
cellular localization as well as the expression levels of wild type
(P2X1WT) and mutated (P2X1delL) P2X1 receptors in trans-
fected HEK293 cells, we produced a polyclonal antibody di-
rected against the extracellular domain of the protein that
recognized both receptors. Immunofluorescence and confocal
microscopy revealed normal membrane localization of the
P2X1delL receptors in stably transfected cells (Fig. 2A), indi-
cating that the mutation does not affect the sorting and/or the
processing of the protein. Western blotting experiments on
membrane and cytosolic cell fractions confirmed membrane
localization of the mutated receptor and showed similar expres-
sion levels for P2X1WT and P2X1delL (Fig. 2B). No P2X1
protein was detected in nontransfected HEK293 cells (Fig. 2, A
and B).
Heterologous Expression of P2X1delL Receptor Creates Non-
functional Channels—Functional comparison of P2X1delL and
P2X1WT was performed in voltage-clamped HEK293 cells
transiently transfected with a bicistronic expression vector en-
coding P2X1delL or P2X1WT together with the GFP. As de-
scribed previously (16), P2X1WT generated a robust, quickly
desensitized, inward current during conventional whole cell
patch clamp measurements. This typical P2X1 phenotype cur-
rent was recorded from all P2X1WT-transfected green cells.
The current density in response to 100 mM ATP was 398.7
pA/pF1 (S.E. 5 91.8 pA/pF, n 5 9) (Fig. 3A) at a holding
potential of 280 mV. Fig. 3B represents instantaneous I-V
relationship before and after ATP application, clearly showing
the reversal of the ATP-induced current at 15 mV, which is
characteristic for P2X1-mediated cation current (17). ADP (50
mM) application induced a current of 333.6 pA/pF (S.E. 5 20.7
pA/pF, n 5 9) with a slower channel desensitization time
course (Fig. 3C). Interestingly, in P2X1delL-transfected cells,
agonist application (50 mM ADP) failed to evoke membrane
currents at identical holding potential (n 5 5) (Fig. 3E), and
100 mM ATP could induce an extremely small inward current in
66% of the transfected cells (current density was 6.89 pA/pF,
S.E. 5 2.34 pA/pF, mean peak current 5 87 pA, n 5 6) (Fig.
3D). The nontransfected HEK293 cells or those cells, which did
not emit green fluorescence, did not respond to agonist appli-
cation (data not shown, n 5 5).
Dominant Negative Effect of P2X1delL on Normal P2X1 Ac-
tivity—Since the P2X receptors have been shown to form stable
homo- or hetero-oligomers in cell membranes (3), we wondered
whether the inactive P2X1delL receptor could disturb P2X1WT
activity in a co-expression system. For this purpose, Xenopus
FIG. 1. Mutation in the patient platelet P2X1 cDNAs. A, the
sequence displays the nucleotides 1026–1069 of the normal P2X1 cDNA
(GenBankTM accession number AF020498). B, mutated fragment con-
taining an in-frame three nucleotide deletion. The position of the trans-
lated leucine residues is indicated. C, schematic representation of the
mutated P2X1 protein structure and the site of the mutation (crossed
open symbol).
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oocytes were co-injected with both receptor cRNAs. Oocytes
expressing P2X1WT receptors alone (10 ng of cRNA) showed
robust ATP-induced whole cell currents with amplitudes in the
range of 1.3–2.4 mA at negative holding potential (mean peak
value taken as 100%) (Fig. 4A), whereas oocytes expressing
P2X1delL (10 ng of cRNA) failed to develop any significant
current, confirming the results observed in HEK293 cells. In
co-expression experiments, maintaining a total amount of in-
jected cRNAs of 10 ng, 5 ng of P2X1WT combined with 5 ng of
P2X1delL cRNAs resulted in a stronger reduction of the peak
current amplitude (to 15%) than expected from injection of 5 ng
of active P2X1WT cRNAs alone. These data indicated a domi-
nant negative effect of the mutated receptor on the normal
P2X1 channel activity. This effect was investigated dose-de-
pendently by co-injecting 10 ng P2X1WT with 10 or 5 ng
P2X1delL cRNAs. Co-injection of 10 ng of P2X1WT with 10 ng
of P2X1delL cRNAs resulted in the development of a current
reduced by 50% compared with the P2X1WT (10 ng) reference
current, whereas co-injection of 10 ng of P2X1WT cRNA with 5
ng of P2X1delL led to 30% reduction, showing dose dependence
of the dominant negative effect.
DISCUSSION
The mutation presently described is an in-frame deletion of
three nucleotides, which results in the loss of one leucine res-
idue (Leu-351, Leu-352, or Leu-353) within a stretch of four
leucine residues located between amino acids 351 and 354 of
the P2X1 receptor. Heterologous expression of the P2X1WT
receptor results in quickly desensitized ATP- or ADP-induced
cation-selective inward rectifying currents. Interestingly,
P2X1delL-expressing HEK293 cells or Xenopus oocytes failed
to develop an ADP- or ATP-induced current. This lack of func-
tion was not due to improper targeting and insertion of the
channel into the plasma membrane as evidenced by confocal
microscopy following immunostaining. The leucine deletion is
located in a domain (TM2 spanning residues 332–357) of P2X1,
which is thought to traverse the lipid membrane, forming part
of the ion-conducting region of every P2X-type receptor (3).
Positioning of the P2X receptor subunit in the membrane has
been assigned from a range of experiments analyzing the effect
of extracellular application of methanethiosulfonates on the
currents evoked by ATP following substitution of residues 316–
354 of P2X2 by cysteine (13, 14). The D349C substitution was
unique as only the smaller ethylamine derivative ((2-aminoeth-
yl)methanethiosulfonate) inhibited the current after channel
opening with ATP, indicating that Asp-349 is located on the
intracellular side of the channel gate. This aspartate residue,
corresponding to Asp-350 of P2X1, and conserved in all P2X
receptors, precedes the leucine deletion identified in P2X1
(Leu-351 to Leu-353) (Fig. 5). The deletion is thus localized in
the inner proximal neighborhood of the intracellular channel
gate (Fig. 5). It is also contained in a stretch of three apolar
residues with conserved hydrophobicity among all P2X recep-
tors. As no P2X2 functional loss was observed when these
residues were substituted in cysteine (13, 14), our findings
imply that the deletion results in the disruption of an impor-
tant channel structure comprising the highly conserved apolar
residue stretch. Thus, our data point to the involvement of
these residues in critical structural attributes of the P2X1
channel and potentially of the other P2X-type channels.
P2X receptor subunits assemble into homo- and hetero-oli-
gomeric channels (3). Co-expression experiments performed in
Xenopus oocytes indicated that the mutant receptor has a dose-
dependent dominant negative effect on the normal P2X1 chan-
FIG. 3. P2X1WT and P2X1delL channel activity in transfected
HEK293 cells. ATP- (100 mM) (A) and ADP- (50 mM) (C) induced inward
currents in P2X1WT-expressing cells. Corresponding I–V curves re-
corded in the presence (ATP) or absence (Control) of 100 mM ATP (B).
Whole cell currents in P2X1delL-expressing HEK293 cells in response
to 100 mM ATP (D) or 50 mM ADP (E). Agonist application is depicted by
arrows, application lasted for 5 s. 2 5 level of zero current.
FIG. 2. Normal membrane localization and expression levels of
P2X1delL. A, confocal microscopy. Immunostaining of the P2X1WT
(WT) and P2X1delL (delL) in stably transfected HEK293 cells. Non-
transfected cells (NT) are shown as negative controls. B, Western blots
performed on P2X1WT and P2X1delL-expressing HEK293 cell extracts
(c, cytosol; m, membrane fraction). Nontransfected (NT) cell membrane
extracts are also shown.
FIG. 4. Co-expression of P2X1WT and P2X1delL receptors in
Xenopus oocytes. A, currents evoked by 100 mM ATP in P2X1WT- and
P2X1delL-expressing oocytes after cytoplasmic microinjection of the
indicated amount of cRNA. Mean peak values (6S.E.) were normalized
to oocytes injected with 10 ng P2X1WT cRNA (100%) and expressed in
percentage. B, corresponding representative inward current profiles.
The left bar corresponds to the zero current level. The arrows represent
the time point of agonist application (*, p , 0.05; **, p , 0.005 versus
the wild type 10 ng reference).
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nel activity. Indeed, the channel phenotype observed after co-
injection of different ratios between the P2X1WT and
P2X1delL subunits leads to a weaker current than expected
from addition of individual subunit phenotypes, indicating that
the mutated subunit dominates the phenotype of the resulting
channel. This dominant negative effect may rely on the fact
that P2X1delL subunits are still able to assemble with the
P2X1WT subunits, forming nonfunctional hetero-oligomers in
oocyte membranes. The chimera study of Torres et al. (9)
showed that TM2 is a critical determinant of P2X subunit
assembly; it seems, however, that amino acid residues distinct
from Leu-351 to Leu-353 of the P2X1 subunit are responsible
for the assembly. Current studies aim at determining whether
the presence of this single leucine deletion in P2X1WT/
P2X1delL hetero-oligomers affects either the single channel
conductance or the probability of channel opening.
In co-immunoprecipitation assays, P2X1 subunits were
shown to assemble with most of the other P2X subunits (P2X2,
P2X3, P2X5, and P2X6) (18), resulting in a channel with a
novel phenotype in the case of P2X5 (19). It would be interest-
ing to determine whether the P2X1delL subunit can still as-
semble with these P2X subunits and abolish the channel activ-
ity. If so, the P2X1 dominant negative mutant would constitute
a novel selective tool that should facilitate the study of the
physiological role not only of P2X1 but also of P2X1-containing
hetero-oligomers and potentially other P2X homo-oligomers in
native cells.
Of interest is the finding that the dominant negative P2X1
mutant was present in the platelets of a patient presenting a
severe bleeding disorder. Indeed, since stimulation of platelets
with ADP or a,b-methylene ATP results in a rapid Ca21 influx
through platelet P2X1 channels (6), a role for this channel in
normal homeostasis can be hypothesized.
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FIG. 5. Sequence alignment of the TM2 of all P2X receptors.
Conserved amino acid residues are boxed with solid lines; the three-
apolar residue stretch is boxed with a dashed line. The position of the
deletion affecting residues Leu-351, Leu-352, or Leu-353 of P2X1 is
depicted with circles.
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